Outcome of allogeneic transplantation for mature T-cell lymphomas: Impact of donor source and disease characteristics Journal Article
| Authors: | Hamadani, M.; Ngoya, M.; Sureda, A.; Bashir, Q.; Litovich, C. A.; Finel, H.; Chen, Y.; Boumendil, A.; Zain, J.; Castagna, L.; Cashen, A. F.; Blaise, D.; Shadman, M.; Pastano, R.; Khimani, F.; Arat, M.; Dietrich, S.; Schmitz, N.; Glass, B.; Kharfan-Dabaja, M. A.; Corradini, P.; Sauter, C. S.; Montoto, S.; Kwon, M.; Herrera, A. F.; Dreger, P. |
| Article Title: | Outcome of allogeneic transplantation for mature T-cell lymphomas: Impact of donor source and disease characteristics |
| Abstract: | Mature T-cell lymphomas constitute the most common indication for allogeneic hematopoietic cell transplantation (allo-HCT) of all lymphomas. Large studies evaluating contemporary outcomes of allo-HCT in mature T-cell lymphomas relative to commonly used donor sources are not available. Included in this registry study were adult patients who had undergone allo-HCT for anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma (AITL), or peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) between 2008 and 2018. Hematopoietic cell transplantation (HCT) platforms compared were posttransplant cyclophosphamide-based haploidentical (haplo-)HCT, matched sibling donor (MSD) HCT, matched unrelated donor HCT with in vivo T-cell depletion (MUD TCD1), and matched unrelated donor HCT without in vivo T-cell depletion (MUD TCD2). Coprimary end points were overall survival (OS) and progression-free survival (PFS); secondary end points included nonrelapse mortality (NRM), and relapse/progression incidence (RI). A total of 1942 patients were eligible (237 haplo-HCT; 911 MSD; 468 MUD TCD1; 326 MUD TCD2). Cohorts were comparable for baseline characteristics with the exception of higher proportions of patients with decreased performance status (PS) and marrow graft recipients in the haplo-HCT group. Using univariate and multivariate comparisons, OS, PFS, RI, and NRM were not significantly different among the haplo-HCT, MSD, MUD TCD1, and MUD TCD2 cohorts, with 3-year OS and PFS of © 2022 by The American Society of Hematology. |
| Keywords: | adolescent; aged; major clinical study; overall survival; mortality; cancer recurrence; progression free survival; cyclophosphamide; retrospective study; peripheral t cell lymphoma; t cell lymphoma; acute graft versus host disease; chronic graft versus host disease; karnofsky performance status; graft versus host reaction; cancer registry; allogeneic hematopoietic stem cell transplantation; t cell depletion; calcineurin inhibitor; adoptive immunotherapy; platelet count; recurrence free survival; unrelated donor; anaplastic large cell lymphoma; angioimmunoblastic t cell lymphoma; mycophenolate mofetil; neutrophil recovery; human; male; female; article; nonrelapse mortality; absolute neutrophil count; haploidentical transplantation; platelet recovery; matched unrelated donor; matched sibling donor |
| Journal Title: | Blood Advances |
| Volume: | 6 |
| Issue: | 3 |
| ISSN: | 2473-9529 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-02-08 |
| Start Page: | 920 |
| End Page: | 930 |
| Language: | English |
| DOI: | 10.1182/bloodadvances.2021005899 |
| PUBMED: | 34861680 |
| PROVIDER: | scopus |
| PMCID: | PMC8945300 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 March 2022 -- Source: Scopus |
